Abstract:BACKGROUND:Recent studies show that mutations in Leucine Rich Repeat Kinase 2 (LRRK2) are the cause of the most common inherited and some sporadic forms of Parkinson's disease (PD). The molecular mechanism underlying the pathogenic role of LRRK2 mutations in PD remains unknown.METHODOLOGY/PRINCIPAL FINDINGS:Using affinity purification and mass spectrometric analysis, we investigated phosphorylation sites and binding proteins of LRRK2 purified from mouse brain. We identified multiple phosphorylation sites at N-terminus of LRRK2 including S910, S912, S935 and S973. Focusing on the high stoichiometry S935 phosphorylation site, we developed an anti-pS935 specific antibody and showed that LRRK2 is constitutively phosphorylated at S935 in various tissues (including brain) and at different ages in mice. We find that 14-3-3 proteins (especially isoforms γ and η) bind LRRK2 and this binding depends on phosphorylation of S935. The binding of 14-3-3, with little effect on dimer formation of LRRK2, confers protection of the phosphorylation status of S935. Furthermore, we show that protein kinase A (PKA), but not LRRK2 kinase itself, can cause the phosphorylation of LRRK2 at S935 in vitro and in cell culture, suggesting that PKA is a potential upstream kinase that regulates LRRK2 function. Finally, our study indicates that the common PD-related mutations of LRRK2, R1441G, Y1699C and G2019S, decrease homeostatic phosphorylation levels of S935 and impair 14-3-3 binding of LRRK2.CONCLUSIONS/SIGNIFICANCE:LRRK2 is extensively phosphorylated in vivo, and the phosphorylation of specific sites (e.g. S935) determines 14-3-3 binding of LRRK2. We propose that 14-3-3 is an important regulator of LRRK2-mediated cellular functions. Our study suggests that PKA, a cAMP-dependent kinase involved in regulating dopamine physiology, is a potential upstream kinase that phosphorylates LRRK2 at S935. Furthermore, the reduction of phosphorylation/14-3-3 binding of LRRK2 due to the common familial PD-related mutations provides novel insight into the pathogenic mechanism of LRRK2-linked PD.

Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease

Clinical and Functional Evidence for the Pathogenicity of the LRRK2 P.arg1067gln Variant

The Role of the LRRK2 Gene in Parkinsonism

Is Glial Dysfunction the Key Pathogenesis of LRRK2-Linked Parkinson's Disease?

“LRRK2: Autophagy and Lysosomal Activity”

LRRK2, a puzzling protein: Insights into Parkinson's disease pathogenesis

How Parkinson's Disease-Linked LRRK2 Mutations Affect Different CNS Cell Types

Leucine-rich Repeat Kinase 2 (LRRK2) Interacts with Parkin, and Mutant LRRK2 Induces Neuronal Degeneration

Clinical characteristics and pathophysiological properties of newly discovered LRRK2 variants associated with Parkinson's disease

Pathogenic LRRK2 compromises the subcellular distribution of lysosomes in a Rab12-RILPL1-dependent manner

Leucine-Rich Repeat Kinases

LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression

Correlation between Mutations in the LRRK2 and Parkinson′s Disease

Kinase Activity of Mutant LRRK2 Mediates Neuronal Toxicity

Advance of the Study on LRRK2 Gene in Parkinson's Disease

Phosphorylation-dependent 14-3-3 Binding to LRRK2 is Impaired by Common Mutations of Familial Parkinson's Disease.

Pathophysiological evaluation of the LRRK2 G2385R risk variant for Parkinson’s disease

LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons

MDSGene update and expansion: Clinical and genetic spectrum of LRRK2 variants in Parkinson's disease

Mutations in LRRK2 linked to Parkinson disease sequester Rab8a to damaged lysosomes and regulate transferrin-mediated iron uptake in microglia

LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice